Navigation Links
BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow
Date:5/20/2011

SAN JOSE, Calif., May 20, 2011 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), launched today the BD FACSVerse™ Flow Cytometer, a flexible, reliable and scalable system that can analyze up to 10 parameters and support a wide range of research applications.  

“We engineered cutting-edge innovation into the BD FACSVerse System from the ground up, with three foundations in mind,” said James Glasscock, President of Cell Analysis, BD Biosciences.  “First, we wanted to provide researchers with a single system that could handle routine applications along with complex multi-color experiments with precision and reproducibility.  Second, we sought to streamline workflow and make the system easy to use with built-in intelligence. Lastly, we wanted to help protect our customers’ investment by giving them an upgrade path from 6 parameters up to 10 parameters as well as multiple optional capabilities that will allow them to meet the future demands of their research.”

With the new BD FACSuite™ Software System for the BD FACSVerse Flow Cytometer, users can now automate routine tasks, such as instrument startup, setup, sample acquisition, and data analysis, and complete others with minimal clicks  The software package's modular architecture enables users to multitask, performing data analysis while the system is acquiring data. According to Glasscock, the software introduces a powerful new paradigm that eliminates the need for daily spill over correction, which is essential for today's multicolor analysis.  BD FACSuite Software enables assays and experiments to be exported to other BD FACSVerse Systems around the globe, minimizing commonly encountered system and user-related variances.

The BD FACSVerse Flow Cytometer has built-in intelligence that is intended to reduce errors, increase efficiency, automate processes and minimize user interaction. Some examples include:

  • Vacuum-based fluidic subsystem that allows exceptional flexibility in sample introduction;
  • New setup and QC concepts that eliminate the need for daily compensation for standard fluorochromes; and,
  • Intelligence and innovation that are built into components across the system that streamline many operations and prevent errors

To support a wide range of applications, the system provides optional predefined BD research assays for apoptosis, cell cycle, cell proliferation, and cytokine detection, which are matched with BD reagent kits for reproducible results. The system also facilitates the development of user-defined experiments.  Researchers can convert their experiments to reusable assays that include relevant settings, acquisition and analysis worksheets, and gating strategies.  They can also establish report parameters to reduce data variability between users and laboratories for the same application.

The BD FACSVerse Flow Cytometer is available in 4-color, 6-color and 8-color configurations with forward-scatter and side-scatter support for up to 10 total parameters. The 4- and 6-color systems can be expanded with a field upgrade. The system has a compact footprint that enables it to fit easily on standard laboratory bench tops.  

For more information on the BD FACSVerse Flow Cytometer, please visit: http://bdbiosciences.com/go/verse

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact: Jeff Ezell
BD Public Relations
(201) 847-5533
Jeff_Ezell@bd.com


'/>"/>
SOURCE BD-Becton Dickinson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Biosciences Acquires Brightwell Technologies
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
5. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
6. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
7. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
10. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
11. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... EAST NORRITON, Pa. , Feb. 8, 2016 ... acquisition of November Research Group (NRG),s pharmacovigilance ... of pharmacovigilance system-related consulting services and an Oracle ... regulatory compliance services to Life Sciences companies. ... acquisition strengthens and expands HighPoint,s life sciences capabilities ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016  As part of ... has announced today the appointment of Lori Chmura ... than 20 years in the industry, Chmura,s extensive experience in ... the advancement of Dune Medical Devices. ... will be responsible for leading all sales, marketing and operational ...
(Date:2/8/2016)... Velano Vascular, a medical technology company transforming ... their practitioners, announced today that the company has raised ... the proceeds from this financing, an extension of a ... to support the development and commercialization of the company,s ... Philadelphia , and a number ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates ... vital new community enrichment program, has teamed up with Citizens Opposed to Domestic Abuse ... from intimate abuse. To support all those victimized by the fear of violence in ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... While a significant number of women and men with eating disorders report a ... that best predicts the development of an eating disorder. , At the ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort ... is time to make a change in public health,” states Carole Baggerly, Director ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
Breaking Medicine News(10 mins):